RxDoctor Payments Data

Ryan Hakimi, DO

Neurocritical Care · Greenville, SCNPI 1780858753

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,879 of the $2,446 with a category attached, or 76.8%. 12 manufacturers reported payments, led by Amgen at 29.3% of the total. Reporting peaked in 2024 at $629 and has fallen 64.9% since, to $221 in 2025.

$2,446in general payments, 2019–2025

Across 23 payments — averaging $106.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$718
  • Irras USA, Inc.$576
  • Cumberland Pharmaceuticals, Inc.$237
  • UCB, Inc.$236
  • Ceribell, Inc.$160
  • AstraZeneca$125
  • plus $394 from 6 others

What the payments were for

  • Speaking & faculty fees$56623%
  • Food & beverage$1,87977%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few neurocritical care providers in South Carolinato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$12,943
Medicare patients
66
Services billed
134

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurocritical care in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →